Griseofulvin Dosing for Tinea Capitis
For tinea capitis, griseofulvin should be dosed at 15-20 mg/kg/day (single or divided dose) for patients under 50 kg, or 1 g/day for those over 50 kg, continued for 6-8 weeks, with the critical caveat that treatment duration must extend to 12-18 weeks for Trichophyton infections due to inferior efficacy against this species. 1
Dosing Algorithm by Body Weight
Children and Adults < 50 kg:
- Standard dose: 15-20 mg/kg/day (can be given as single daily dose or divided)
- Duration: 6-8 weeks for Microsporum species
- Resistant cases: Increase to 25 mg/kg/day for prolonged periods 1
Adults and Children ≥ 50 kg:
- Dose: 1 g/day (single or divided dose)
- Duration: 6-8 weeks 1
Species-Specific Treatment Modifications
The causative organism fundamentally determines treatment success. Griseofulvin achieves 88.5% response rates for Microsporum species but only 67.9% for Trichophyton species 1. This disparity is clinically critical:
For Microsporum infections (M. canis, M. audouinii):
- Use standard dosing for 6-8 weeks
- Griseofulvin is the preferred first-line agent 1
- Meta-analysis confirms 8 weeks of griseofulvin significantly outperforms 4 weeks of terbinafine 1
For Trichophyton infections (T. tonsurans, T. violaceum, T. soudanense):
- Extend treatment to 12-18 weeks due to reduced clinical efficacy 1
- Consider terbinafine as superior alternative for these species 1
- Higher doses (up to 25 mg/kg/day) may be necessary 1
Administration and Bioavailability Enhancement
Take griseofulvin with fatty food to significantly increase absorption and bioavailability 1. In pediatric studies, administration with milk resulted in 4-fold higher peak serum concentrations and 10-fold greater area under the curve compared to fasting administration 2. This is not optional—it directly impacts treatment success.
Treatment Initiation
Start treatment empirically when clinical features strongly suggest tinea capitis (scaling, lymphadenopathy, alopecia, or kerion present) without waiting for culture results, which take 2-4 weeks 1. However, always obtain scalp scrapings, hair plucks, or brush samples for microscopy and culture before starting therapy to guide species-specific treatment adjustments 1.
Monitoring and Treatment Endpoints
The endpoint is mycological cure, not clinical improvement 1. This is a common pitfall—patients may appear clinically improved while remaining culture-positive and infectious.
- Repeat mycology sampling until mycological clearance is achieved 1
- If clinical improvement occurs but mycology remains positive, continue current therapy for an additional 2-4 weeks 1
- If no initial clinical improvement, switch to second-line therapy (itraconazole 5 mg/kg/day for 2-4 weeks) 1
Treatment Failure Management
When treatment fails, systematically evaluate:
- Compliance issues (prolonged treatment affects adherence)
- Suboptimal absorption (ensure taking with fatty food)
- Wrong species (Trichophyton requires longer treatment or alternative agent)
- Reinfection (screen household contacts for T. tonsurans) 1
Contraindications and Drug Interactions
Absolute contraindications: Lupus erythematosus, porphyria, severe liver disease 1
Critical drug interactions:
- Rifampicin decreases griseofulvin plasma concentrations (avoid combination)
- Cimetidine increases griseofulvin levels 1
Adjunctive Measures
Add antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission, though topical therapy alone is insufficient for cure 1. Children on appropriate therapy should attend school or nursery 1.
FDA-Approved Dosing (Pediatric > 2 years)
The FDA label specifies 10 mg/kg/day as adequate for pediatric patients, with weight-based recommendations: 125-250 mg daily for 30-50 lbs, and 250-500 mg daily for over 50 lbs, given in divided doses 2. However, the British Association of Dermatologists guideline recommends the higher 15-20 mg/kg/day range based on superior clinical evidence 1.